Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
OwnerAnanda Chakrabarty, Tapas Das Gupta +4inventors
InventorsAnanda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Anita Chaudhari, Arsenio Fialho, Yonghua Zhu
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof to treat cancer in mammals.
Claims8
A pharmaceutical composition for administration to a mammalian patient comprising:
- an amino acid sequence that binds to either an ephrin or an Eph receptor and has been modified, wherein the amino acid sequence is a truncation of cupredoxin consisting of a sequence selected from the group consisting of:
- SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 29, and SEQ ID NO:
- 30 and wherein the modification is selected from the group consisting of:
- glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation, ADP-ribosylation, amidation, acetylation, polyethylene glycol (PEG) modification, and phosphorylation;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition for administration to a mammalian patient comprising:
- an amino acid sequence that binds to either an ephrin or an Eph receptor and has been modified, wherein the amino acid sequence is a truncation of cupredoxin consisting of a sequence selected from the group consisting of:
- SEQ ID NO:
- 28 and SEQ ID NO:
- 32 and wherein the modification is selected from the group consisting of:
- glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation, ADP- ribosylation, amidation, acetylation, polyethylene glycol (PEG) modification, and phosphorylation;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.